2519: Development of De Novo Donor-Specific HLA Antibodies After Combined Intestinal and Vascularized Composite Allotransplantation

Vascularized Composite Allotransplantation
doi 10.1080/23723505.2016.1232937
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

De Novo Belatacept in Clinical Vascularized Composite Allotransplantation

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2018English

Below the Waterline-The Danger of De Novo Donor-Specific HLA Antibodies

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2012English

In Situ Recruitment of Regulatory T Cells Promotes Donor-Specific Tolerance in Vascularized Composite Allotransplantation

Science advances
Multidisciplinary
2020English

Preclinical Models in Vascularized Composite Allotransplantation

Current Transplantation Reports
2015English

What Stimulates the Development of De Novo Donor Specific Antibodies in Cardiac Transplant Recipients?

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Donor-Specific Anti-Hla Antibodies and …Recipient-Specific Anti-Hla Antibodies? The Conundrum on Pregnancy in Transplantation

American Journal of Hematology
Hematology
2020English

Utility of Protocol Kidney Biopsies for De Novo Donor Specific Antibodies

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2017English

De-Novo Donor Specific DQ Antibody in AMR and Need for Extended HLA Typing

Hematology & Transfusion International Journal
2017English

Sensitization and Desensitization of Burn Patients as Potential Candidates for Vascularized Composite Allotransplantation

Burns
MedicineSurgeryCritical CareEmergency MedicineIntensive Care Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy